Duchenne Muscular Dystrophy (Genitourinary Disorders) - Drugs In Development, 2021

July 2021 | 489 pages | ID: D898A870BB32EN
Global Markets Direct

Abstracts

Duchenne Muscular Dystrophy (Genitourinary Disorders) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Drugs In Development, 2021, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 5, 14, 10, 3, 68, 27 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 2, 1, 12 and 2 molecules, respectively.

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Duchenne Muscular Dystrophy - Overview
Duchenne Muscular Dystrophy - Therapeutics Development
Duchenne Muscular Dystrophy - Therapeutics Assessment
Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development
Duchenne Muscular Dystrophy - Drug Profiles
Duchenne Muscular Dystrophy - Dormant Projects
Duchenne Muscular Dystrophy - Discontinued Products
Duchenne Muscular Dystrophy - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Duchenne Muscular Dystrophy, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Duchenne Muscular Dystrophy - Pipeline by 4D Molecular Therapeutics Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by AAVogen Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by Alpha Anomeric, 2021
Duchenne Muscular Dystrophy - Pipeline by American CryoStem Corp, 2021
Duchenne Muscular Dystrophy - Pipeline by Anagenesis Biotechnologies SAS, 2021
Duchenne Muscular Dystrophy - Pipeline by Antisense Therapeutics Ltd, 2021
Duchenne Muscular Dystrophy - Pipeline by Astellas Gene Therapies, 2021
Duchenne Muscular Dystrophy - Pipeline by AUM LifeTech Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by Autotac Bio Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by Avidity Biosciences Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by Axolo Pharma Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by Bayer AG, 2021
Duchenne Muscular Dystrophy - Pipeline by Biogen Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by BioIncept LLC, 2021
Duchenne Muscular Dystrophy - Pipeline by Bioleaders Corp, 2021
Duchenne Muscular Dystrophy - Pipeline by BioMarin Pharmaceutical Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by Biophytis SA, 2021
Duchenne Muscular Dystrophy - Pipeline by Capricor Therapeutics Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by Chengdu Fanxi Biopharma Co Ltd, 2021
Duchenne Muscular Dystrophy - Pipeline by Code Biotherapeutics Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by Consortium.AI, 2021
Duchenne Muscular Dystrophy - Pipeline by Constant Therapeutics LLC, 2021
Duchenne Muscular Dystrophy - Pipeline by Tivorsan Pharmaceuticals Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by Tolerion Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by Triplex Therapeutics Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by UGISense AG, 2021
Duchenne Muscular Dystrophy - Pipeline by Ultragenyx Pharmaceutical Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by Vertex Pharmaceuticals Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by Vita Therapeutics Inc, 2021
Duchenne Muscular Dystrophy - Pipeline by Wave Life Sciences Ltd, 2021
Duchenne Muscular Dystrophy - Pipeline by Zata Pharmaceuticals Inc, 2021
Duchenne Muscular Dystrophy - Dormant Projects, 2021
Duchenne Muscular Dystrophy - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Duchenne Muscular Dystrophy, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021